Pricing Log in Create free account
Friday 6 November 2026 Export ARQT’s income statement to Excel — free account

Arcutis Biotherapeutics, Inc.

ARQT Healthcare Biotechnology

Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.

Revenue
+45.1%
EPS
+12.0%
Free cash flow
+1,171.9%
Total debt
+0.83%

Quarter to September 2026, against a year earlier

25.55 1.45 −5.37%
Market cap
$3.4B
P/E
112×
Fwd P/E
81.2×
Dividend yield
—
F-score
4/9
Altman Z
6.98
Beneish M
−1.52
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Arcutis Biotherapeutics, Inc. (ARQT) Revenue

Alert me on Revenue

Arcutis Biotherapeutics, Inc.'s revenue for fiscal 2025 was $376.1M, up 91.3% from $196.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $508.7M. Revenue has risen for 3 consecutive fiscal years. Arcutis Biotherapeutics, Inc. ranks 39th of 390 Biotechnology companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $376.1M 91.34%
FY2024 $196.5M 229.74%
FY2023 $59.6M 1,517.09%
FY2022 $3.7M —

Quarterly newest first

Period Revenue Change
Sep 2026 $143.9M 10.83%
Jun 2026 $129.9M 23.21%
Mar 2026 $105.4M (18.61%)
Dec 2025 $129.5M 30.52%
13 more quarters

Revenue against peers

Company Revenue
LEGN Legend Biotech Corporation Sponsored ADR compare $1.3B
ARQT Arcutis Biotherapeutics, Inc. $508.7M
IOVA Iovance Biotherapeutics, Inc. compare $379.0M
ABCL AbCellera Biologics Inc. compare $66.2M
TNGX Tango Therapeutics, Inc. compare $62.4M
RLAY Relay Therapeutics, Inc. compare $11.0M
DNTH Dianthus Therapeutics, Inc. compare $2.7M
DFTX Definium Therapeutics, Inc. compare —
EWTX Edgewise Therapeutics, Inc. compare —

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on ARQT